LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 43, 2014, Pages 15573-15578

  Rothaug, Michelle ^a   Zunke, Friederike ^a   Mazzulli, Joseph R ^b   Schweizer, Michaela ^c   Altmeppen, Hermann ^c   Lüllmann Rauche, Renate ^a   Kallemeijn, Wouter W ^d   Gaspar, Paulo ^e   Aerts, Johannes M ^d   Glatzel, Markus ^c   Saftig, Paul ^a   Krainc, Dimitri ^b   Schwake, Michael ^a,f   Blanz, Judith ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF PORTO   (Portugal)

^f BIELEFELD UNIVERSITY   (Germany)

Author keywords

AMRF; C57 BL6 J; GD; PME; SCARB2

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; MESSENGER RNA; PROTEIN; PROTEIN LIMP 2; UNCLASSIFIED DRUG; LIPID; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; NEUROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; AUTOPHAGOSOME; AUTOPHAGY; BRAIN STEM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GLIOSIS; HELA CELL LINE; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; LYSOSOME MEMBRANE; MESENCEPHALON; METABOLIC CLEARANCE RATE; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROTOXICITY; NICK END LABELING; NONHUMAN; PARESIS; PARKINSON DISEASE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PONS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPLICATION; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; LYSOSOME; METABOLISM; NERVE CELL; PATHOLOGY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; AUTOPHAGY; BRAIN STEM; GLIOSIS; GLUCOSYLCERAMIDASE; HUMANS; LIPIDS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MICE, INBRED C57BL; NEURONS; NEUROTOXINS;

EID: 84908282747     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405700111     Document Type: Article

References (51)

1. Reczek D, et al. (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131(4):770-783.
2. Balreira A, et al. (2008) A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum Mol Genet 17(14):2238-2243.
3. Berkovic SF, et al. (2008) Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet 82(3):673-684.
4. Gamp AC, et al. (2003) LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum Mol Genet 12(6):631-646.
5. Dibbens LM, et al. (2009) SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. Ann Neurol 66(4):532-536.
6. Fu YJ, et al. (2014) Progressive myoclonus epilepsy: Extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations. Neuropathol Appl Neurobiol 40(5):551-563.
7. Blanz J, et al. (2010) Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. Hum Mol Genet 19(4):563-572.
8. Zachos C, Blanz J, Saftig P, Schwake M (2012) A critical histidine residue within LIMP-2 mediates pH sensitive binding to its ligand β-glucocerebrosidase. Traffic 13(8):1113-1123.
9. Neculai D, et al. (2013) Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 504(7478):172-176.
10. Westbroek W, Gustafson AM, Sidransky E (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 17(9):485-493.
11. Velayati A, et al. (2011) A mutation in SCARB2 is a modifier in Gaucher disease. Hum Mutat 32(11):1232-1238.
12. Wong K, et al. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82(3):192-207.
13. Manning-Boʇ AB, Schüle B, Langston JW (2009) Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism. Neurotoxicology 30(6):1127-1132.
14. Mazzulli JR, et al. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146(1):37-52.
15. Xu YH, et al. (2011) Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 102(4):436-447.
16. Sardi SP, et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 110(9):3537-3542.
17. Do CB, et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 7(6):e1002141.
18. Hopfner F, et al. (2013) The role of SCARB2 as susceptibility factor in Parkinson's disease. Mov Disord 28(4):538-540.
19. Bras J, et al. (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet, 10.1093/hmg/ddu334.
20. Specht CG, Schoepfer R (2001) Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci 2:11.
21. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27(12):3338-3346.
22. Witte MD, et al. (2010) Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol 6(12):907-913.
23. Adachi Y, et al. (1998) An autopsy case of fetal Gaucher disease. Acta Paediatr Jpn 40(4):374-377.
24. Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1(1):11.
25. Dehay B, et al. (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci USA 109(24):9611-9616.
26. Ramonet D, et al. (2012) PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet 21(8):1725-1743.
27. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114(Pt 5):2283-2301.
28. Rieker C, et al. (2011) Neuropathology in mice expressing mouse alpha-synuclein. PLoS ONE 6(9):e24834.
29. Shimshek DR, Schweizer T, Schmid P, van der Putten PH (2012) Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1. Sci Rep 2:262.
30. Devine MJ, Gwinn K, Singleton A, Hardy J (2011) Parkinson 's disease and alpha-synuclein expression. Movement Dis 26(12):2160-2168.
31. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL (2004) Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25(5):761-769.
32. Ubhi K, et al. (2010) Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport 21(6):457-462.
33. Giasson BI, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34(4):521-533.
34. Lee MK, et al. (2002) Human alpha-synuclein-harboring familial Parkinson' s disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99(13):8968-8973.
35. Gegg ME, et al. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72(3):455-463.
36. Murphy KE, et al. (2014) Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 137(Pt 3):834-848.
37. Osellame LD, et al. (2013) Mitochondria and quality control defects in a mouse model of Gaucher disease - Links to Parkinson's disease. Cell Metab 17(6):941-953.
38. Ginns EI, et al. (2014) Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol Genet Metab 111(2):152-162.
39. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E (2010) Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120(5):641-649.
40. Yap TL, et al. (2011) Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 286(32):28080-28088.
41. Ron I, Rapaport D, Horowitz M (2010) Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease. Hum Mol Genet 19(19):3771-3781.
42. Lesage S, et al.; French Parkinson's Disease Genetics Study Group (2011) Large-scale screening of the Gaucher' s disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 20(1):202-210.
43. Sun Y, et al. (2010) Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet 19(4):634-647.
44. Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19(8):983-997.
45. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M (1994) Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 89(5):347-352.
46. Ramirez A, et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38(10):1184-1191.
47. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D (2012) Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci 32(12):4240-4246.
48. Sevlever D, Jiang P, Yen SH (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47(36):9678-9687.
49. Sun Y, et al. (2010) Neuronopathic Gaucher disease in the mouse: Viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 19(6):1088-1097.
50. Maniwang E, Tayebi N, Sidransky E (2013) Is Parkinson disease associated with lysosomal integral membrane protein type-2?: Challenges in interpreting association data. Mol Genet Metab 108(4):269-271.
51. Blanz J, et al. (2008) Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum Mol Genet 17(22):3437-3445.